Curium and Lantheus announced a definitive agreement under which Curium will buy all outstanding Lantheus shares for $102.50 each in cash at closing, with potential contingent value rights that could lift the total value to about $8 billion. The transaction is expected to close in the first half of 2027, subject to Lantheus shareholder approval and regulatory clearances. The tie-up would combine Curium’s global manufacturing and theranostics footprint with Lantheus’ U.S. radiodiagnostics franchise, including prostate cancer imaging agent Pylarify and cardiac ultrasound agent Definity. Lantheus has indicated it will suspend 2026 guidance due to the pending deal and will release second-quarter results without an investor call. Analysts framed the logic around end-to-end coverage across nuclear medicine supply chain capabilities and broader commercial reach for theranostics and diagnostics products.